Abstract
With the first HCV protease inhibitors approved in 2011, we are currently in a transition phase towards a shift in treatment paradigm. Within the next 3 years, the vast majority of patients with hepatitis C will probably be treated with completely different drugs in most Western countries.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have